Table 9.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Liver Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		3,440	3,652	3,934	4,080	4,187	4,516	4,749	4,989	5,188	5,330
Tx with Antirejection Treatments		1,707	1,566	1,338	1,307	1,332	1,188	1,474	1,503	1,426	1,305
Antibodies	Category Usage	35.4%	30.3%	21.9%	13.3%	12.1%	13.0%	12.4%	14.5%	16.7%	17.5%
	ALG	0.7%	1.4%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	2.7%	2.5%	1.4%	2.1%	1.4%	1.4%	0.7%	0.5%	0.5%	0.6%
	OKT3	33.5%	28.0%	20.4%	11.9%	11.1%	9.7%	6.8%	6.3%	6.7%	6.0%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	1.4%	3.2%	5.1%	5.5%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.2%	0.9%	1.7%	2.4%	1.6%	1.9%
	Simulect	0.0%	0.1%	0.0%	0.0%	0.1%	1.2%	3.1%	3.1%	4.2%	4.1%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
Corticosteroids	Category Usage	89.0%	86.0%	83.6%	83.7%	83.7%	87.2%	89.3%	90.6%	88.8%	90.3%
	Steroids	89.0%	86.0%	83.6%	83.7%	83.7%	87.2%	89.3%	90.6%	88.8%	90.3%
Antimetabolites	Category Usage	0.6%	0.4%	0.6%	0.2%	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%
	Cytoxan	0.6%	0.4%	0.6%	0.2%	0.7%	0.3%	0.2%	0.1%	0.1%	0.0%
	Methotrexate	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.